Drug Trial Radar · NCT05354141
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
970
Planned (sponsor's estimate)
Start
Jul 1, 2022
Primary completion
Nov 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Direct Biologics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Conditions
- Acute Respiratory Distress Syndrome
- ARDS
Interventions
ExoFloBiological
Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Intravenous normal salineOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of 60-day All-cause MortalityTime frame: 60 days
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Direct Biologics Investigational Site
Phoenix, Arizona · Recruiting
Direct Biologics Investigational Site
Little Rock, Arkansas · Recruiting
Direct Biologics Investigational Site
Davis, California · Recruiting
Direct Biologics Investigational Site
Irvine, California · Recruiting
Direct Biologics Investigational Site
Sacramento, California · Recruiting
Direct Biologics Investigational Site
Washington D.C., District of Columbia · Recruiting
Direct Biologics Investigational Site
Jacksonville, Florida · Recruiting
Direct Biologics Investigational Site
Boise, Idaho · Recruiting
Direct Biologics Investigational Site
Iowa City, Iowa · Recruiting
Direct Biologics Investigational Site
Silver Spring, Maryland · Recruiting
Direct Biologics Investigational Site
Boston, Massachusetts · Recruiting
Direct Biologics Investigational Site
Burlington, Massachusetts · Recruiting
Direct Biologics Investigational Site
Springfield, Massachusetts · Recruiting
Direct Biologics Investigational Site
Detroit, Michigan · Recruiting
Direct Biologics Investigational Site
Rochester, Minnesota · Recruiting
Direct Biologics Investigational Site
Jackson, Mississippi · Recruiting
Direct Biologics Investigational Site
Flushing, New York · Recruiting
Direct Biologics Investigational Site
Queens, New York · Recruiting
Direct Biologics Investigational Site
The Bronx, New York · Recruiting
Direct Biologics Investigational Site
Durham, North Carolina · Recruiting
Direct Biologics Investigational Site
Winston-Salem, North Carolina · Recruiting
Direct Biologics Investigational Site
Cincinnati, Ohio · Recruiting
Direct Biologics Investigational Site
Cleveland, Ohio · Recruiting
Direct Biologics Investigational Site
Portland, Oregon · Recruiting
Direct Biologics Investigational Site
Charleston, South Carolina · Recruiting
Direct Biologics Investigational Site
Knoxville, Tennessee · Recruiting
Direct Biologics Investigational Site
Nashville, Tennessee · Recruiting
Direct Biologics Investigational Site
Dallas, Texas · Recruiting
Direct Biologics Investigational Site
Fort Worth, Texas · Recruiting
Direct Biologics Investigational Site
Houston, Texas · Recruiting
Direct Biologics Investigational Site
Murray, Utah · Not yet recruiting
Direct Biologics Investigational Site
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.